TW202321270A - 使用三硫化合物之防止肝細胞增殖因子中之酪胺酸殘基之硝基化的方法 - Google Patents

使用三硫化合物之防止肝細胞增殖因子中之酪胺酸殘基之硝基化的方法 Download PDF

Info

Publication number
TW202321270A
TW202321270A TW111134055A TW111134055A TW202321270A TW 202321270 A TW202321270 A TW 202321270A TW 111134055 A TW111134055 A TW 111134055A TW 111134055 A TW111134055 A TW 111134055A TW 202321270 A TW202321270 A TW 202321270A
Authority
TW
Taiwan
Prior art keywords
trisulfide
pharmaceutically acceptable
acceptable salt
compound
nitration
Prior art date
Application number
TW111134055A
Other languages
English (en)
Chinese (zh)
Inventor
辰巳隆一
中村真子
大島悦男
Original Assignee
國立大學法人九州大學
日商協和發酵生化股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立大學法人九州大學, 日商協和發酵生化股份有限公司 filed Critical 國立大學法人九州大學
Publication of TW202321270A publication Critical patent/TW202321270A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D341/00—Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111134055A 2021-09-09 2022-09-08 使用三硫化合物之防止肝細胞增殖因子中之酪胺酸殘基之硝基化的方法 TW202321270A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021146753 2021-09-09
JP2021-146753 2021-09-09

Publications (1)

Publication Number Publication Date
TW202321270A true TW202321270A (zh) 2023-06-01

Family

ID=85506410

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111134055A TW202321270A (zh) 2021-09-09 2022-09-08 使用三硫化合物之防止肝細胞增殖因子中之酪胺酸殘基之硝基化的方法

Country Status (6)

Country Link
US (1) US20240374561A1 (https=)
EP (1) EP4400103A4 (https=)
JP (1) JP7659282B2 (https=)
CN (1) CN117915911A (https=)
TW (1) TW202321270A (https=)
WO (1) WO2023038088A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4647072A1 (en) * 2023-03-07 2025-11-12 Kyowa Hakko Bio Co., Ltd. Enhancer of physiological activity of hepatocyte growth factor
WO2025028521A1 (ja) 2023-08-01 2025-02-06 キリンホールディングス株式会社 肝機能障害の予防又は改善用組成物
CN118515869A (zh) * 2024-05-11 2024-08-20 四川大学 一种多硫化物聚合物、其制备方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5442173B2 (ja) * 2000-09-14 2014-03-12 敏一 中村 筋萎縮性側索硬化症治療剤
WO2018091689A1 (en) * 2016-11-17 2018-05-24 Cytoo Skeletal muscle hypertrophy inducers
EP3560947B1 (en) 2016-12-20 2022-08-24 Kyowa Hakko Bio Co., Ltd. Crystal of glutathione trisulfide dihydrate and method for producing same
JP2022074166A (ja) * 2019-01-30 2022-05-18 協和発酵バイオ株式会社 ポリスルフィド化合物を含有する組成物
CN113354615B (zh) * 2020-03-02 2023-11-03 亚宝药业集团股份有限公司 一种α-硫辛酸杂质A的光化学制备方法
JP7842033B2 (ja) * 2020-05-12 2026-04-07 ザ ジェネラル ホスピタル コーポレイション 神経保護におけるグルタチオントリスルフィド（ｇｓｓｓｇ）
US12552764B2 (en) * 2020-08-27 2026-02-17 Kyowa Pharma Chemical Co., Ltd. Trisulfide compound and clathrate thereof
EP4342464A4 (en) * 2021-07-08 2025-06-04 Kyowa Pharma Chemical Co., Ltd. PROPHYLACTIC OR THERAPEUTIC MEDICINE FOR PARKINSON'S DISEASE

Also Published As

Publication number Publication date
JPWO2023038088A1 (https=) 2023-03-16
CN117915911A (zh) 2024-04-19
WO2023038088A1 (ja) 2023-03-16
EP4400103A4 (en) 2025-08-20
JP7659282B2 (ja) 2025-04-09
US20240374561A1 (en) 2024-11-14
EP4400103A1 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
TW202321270A (zh) 使用三硫化合物之防止肝細胞增殖因子中之酪胺酸殘基之硝基化的方法
JP4344235B2 (ja) タキソール増強剤化合物
US7001923B2 (en) Taxol enhancer compounds
US20030195258A1 (en) Taxol enhancer compounds
EP2018165B1 (fr) COMPOSES DIMERES AGONISTES DES RECEPTEURS DES FGFs
EP3267985A2 (en) 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
AU2002354641A1 (en) Taxol enhancer compounds
JP2001524929A (ja) アミド類
EP4647072A1 (en) Enhancer of physiological activity of hepatocyte growth factor
CN108863994A (zh) 牛蒡子苷元类化合物及其制备方法和用途
CN109836356A (zh) 一种芳甲醚衍生物及其应用
HK1060117B (en) Taxol enhancer compounds